From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

키워드

참고문헌 (20)

1. Younossi ZM, "The global epidemiology of nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH) : a systematic review", Hepatology, 77, pp.1335~1347 (2023)
2. Alqahtani SA, "Hepatic outcomes of nonalcoholic fatty liver disease including cirrhosis and hepatocellular carcinoma", Clin Liver Dis, 27, pp.211~223 (2023)
3. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
4. Rinella ME, "A multi-society Delphi consensus statement on new fatty liver disease nomenclature", Hepatology (2023)[DOI]
5. Rinella ME, "A multi-society Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol (2023)[DOI]
6. Gi-Ae Kim, "Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity", Clinical and Molecular Hepatology, 29(4), pp.831~843 (2023), 대한간학회
7. Peter Konyn, "Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.43~57 (2023), 대한간학회
8. Huang Q, "NAFLD or MAFLD: Which has closer association with all-cause and cause-specific mortality?-results from NHANES III", Front Med(Lausanne), 8, pp.693507~ (2021)
9. Cameron Gofton, "MAFLD: How is it different from NAFLD?", Clinical and Molecular Hepatology, 29, pp.17~31 (2023), 대한간학회
10. Wei S, "The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer", Front Endocrinol(Lausanne), 14, pp.985858~ (2023)
11. Huang JF, "Community-centered disease severity assessment of metabolic dysfunction-associated fatty liver disease", J Clin Transl Hepatol, 11, pp.1061~1068 (2023)
12. Schneider KM, "A new era for steatotic liver Disease : Evaluating the Novel nomenclature in the UK Biobank", J Hepatol (2023)[DOI]
13. Younossi ZM, "A global survey of physicians knowledge about nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.e1456~e1468 (2022)
14. Yu ML, "Path from the discovery to the elimination of hepatitis C virus : Honoring the winners of the Nobel Prize in Physiology or Medicine 2020", Kaohsiung J Med Sci, 37, pp.7~11 (2021)
15. Younossi ZM, "Systematic review with meta-analysis : extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia", Aliment Pharmacol Ther, 49, pp.644~653 (2019)
16. Jang TY, "Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes", Kaohsiung J Med Sci, 38, pp.897~906 (2022)
17. Huang CF, "Cure or curd : Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication", Kaohsiung J Med Sci, 36, pp.920~928 (2020)
18. Yu Jun Wong, "Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis", Clinical and Molecular Hepatology, 29(3), pp.705~720 (2023), 대한간학회
19. Li J, "Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B", J Infect Dis, 224, pp.294~302 (2021)
20. Huang SC, "Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B", Hepatol Int (2023)[DOI]